Off-target development webinar – Specificity screening of therapeutic antibodies to avoid off-target liabilities
Our webinar on 6th May will feature a guest speaker from NanoMab Technology Limited discussing their experience of off-target safety assessment of biologics.
- Understand how the specificity data generated with Cell Microarray screening is used in lead candidate selection and safety assessment
- Learn how IND-enabling specificity data supports submissions to regulators as either an adjunct to, or replacement for, tissue cross reactivity studies
- Learn more about identifying and mitigating the risk of clinical toxicity caused by off-target effects of antibodies and related molecules
To register for the webinar, click here.
If you would like to discuss a project, please get in touch.